Compare Godaddy Inc (GDDY) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Gilead Sciences, Inc. — how do they compare? Godaddy Inc trades at $91.07 (market cap $11.49B), while Gilead Sciences, Inc. trades at $135.96 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 14.7× Godaddy Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals.
| GDDY | GILD | |
|---|---|---|
Market Cap | $11.49B | $168.35B |
Sector | Technology | Health |
52-Week High | $148.88 | $155.80 |
52-Week Low | $75.07 | $110.56 |
Enterprise Value | $14.18B | $191.42B |
Dividend Yield | — | 2.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $90.78, down 0.78% on the day, with a bearish technical signal and mixed sentiment due to ongoing securities investigations. Fundamentally, the company shows strength with consistent earnings beats, revenue growth to $4.95B in 2025, and robust profitability margins. The stock trades at a P/E of 13.48, below the sector average, while analyst consensus targets $112.13, implying significant upside.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but near-term volatility is likely from legal overhangs and technical resistance. Key risks include potential litigation outcomes and competitive pressures in web services. Upside hinges on continued execution and clearing regulatory concerns.
Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.
Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
